SWOG clinical trial number
S2015
MELANOMA MARGINS TRIAL (MELMART-II): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1CM V 2CM Wide Excision Margins for Primary Cutaneous Melanoma
Open
Phase
Abbreviated Title
MELMART-II: A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1CM V 2CM Wide Excision Margins for Primary Cutaneous Melanoma
Status Notes
Please see CTSU.org for: 02.18 MelMarT-II Protocol and Appendix for U.S. Sites Participating
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS
Research committees
Melanoma
Eligibility Criteria Expand/Collapse
For a comprehensive list, see Section 5 of the main protocol (02.18 MelMarT-II Protocol).
Each of the criteria in Section 5 of the main protocol (02.18 MelMarT-II Protocol) must be met in order for a participant to be considered eligible for registration in OPEN.
Each of the criteria in Section 5 of the main protocol (02.18 MelMarT-II Protocol) must be met in order for a participant to be considered eligible for registration in OPEN.
Other Clinical Trials
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
94%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase